Abstract
By employing a new semi-quantitative assay system that includes co-culturing leukemia cells with the mouse bone marrow-derived stromal cell line MS-5, we examined the suppressive effect of a selective inhibitor of ABL tyrosine kinase, STI571, on acute lymphoblastic leukemia (ALL) cells with BCR-ABL fusion. Leukemic blast cells from eight patients with B-precursor ALL, including three patients with BCR-ABL-positive ALL, were cultured on monolayers of MS-5 cells for 3 weeks with or without addition of variable amounts of STI571. In all cases, cobblestone areas (CAs) were formed, showing clear linear cell dose-dependent curves, allowing quantitative assessment of blast cell growth. The progenitor frequencies obtained by this direct CA-forming cell (CAFC) assay were equivalent to ALL progenitor frequencies assessed by the standard limiting dilution assay. The number of CAFCs ranged from 12.3 to 140.3/104 cells. In BCR-ABL-positive ALL patients, CA-containing cells were examined by FISH, and all contained BCR-ABL fusion genes. STI571 inhibited CA formation of BCR-ABL-positive ALL cells virtually 100% at 0.1–1.0 μmol/l. None of the five BCR-ABL-negative ALL patients showed this growth inhibition by STI571 at 0.1–1.0 μmol/l. Our results indicate that STI571 selectively inhibits in vitro growth of BCR-ABL-positive ALL cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pui CH, Evans WE . Acute lymphoblastic leukemia N Engl J Med 1998 339: 605–615
Laport GF, Larson RA . Treatment of adult acute lymphoblastic leukemia Semin Oncol 1997 24: 70–82
Copelan EA, McGuire EA . The biology and treatment of acute lymphoblastic leukemia in adults Blood 1995 85: 1151–1168
Melo JV . The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype Blood 1996 88: 2375–2384
Konopka JB, Watanabe SM, Witte ON . An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity Cell 1984 37: 1035–1042
Daley GQ, Van Etten RA, Baltimore D . Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome Science 1990 247: 824–830
Scott ML, Van Etten RA, Daley GQ, Baltimore D . v-abl causes hematopoietic disease distinct from that caused by bcr-abl Proc Natl Acad Sci USA 1991 88: 6506–6510
Lugo TG, Pendergast AM, Muller AJ, Witte ON . Tyrosine kinase activity and transformation potency of bcr-abl oncogene products Science 1990 247: 1079–1082
Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, Rizzoli V . Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patient after in vitro treatment with the tyrosine kinase inhibitor genistein Blood 1996 88: 3091–3100
Okabe M, Uehara Y, Miyagishima T, Itaya T, Tanaka M, Kuni-Eda Y, Kurosawa M, Miyasaki T . Effect of herbimycin A, an antagonist of tyrosine kinase on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retrovial vector expressing oncoprotein p210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth Blood 1992 80: 1330–1338
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 1996 2: 561–566
Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB . Inhibition of the Abl protein tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 1996 56: 100–104
Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB . Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis Blood Cells Mol Dis 1997 23: 380–394
Deininger MW, Goldman JM, Lydon N, Melo JV . The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells Blood 1997 90: 3691–3698
Dan S, Naito M, Tsuruo T . Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148 Cell Death Differ 1998 5: 710–715
Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ . CGP57148, tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins Blood 1997 90: 4947–4952
Tomason MH, Williams IR, Hasserjian R, Udomsakidi C, McGrath SM, Schwaller J, Druker BJ, Gilliland DG . TEL/PDGFR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor Blood 1999 93: 1707–1714
Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ . Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood 2000 96: 925–932
Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB . Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 2000 295: 139–145
Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J, Sawyers CL . Clinical efficacy and safety of an ABL specific tyrosine kynase inhibitor as targeted therapy for chronic myelogenous leukemia Blood 1999 94: 368a (Abstr.)
Druker BJ, Kantarjian H, Sawyers CL, Resta D, Reese SF, Ford J, Talpaz M . Activity of an ABL specific tyrosine kinase inhibitor in patients with bcr-abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis Blood 1999 94: 697a (Abstr.)
Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D . Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia Blood 1992 79: 2370–2377
Campana D, Coustan-Smith E, Manabe A, Kumagai M, Murti KG, Silvennoinen O, Nishigaki H, Kitanaka A, Ito C . Human B-cell progenitors and bone marrow microenvironment Hum Cell 1996 9: 317–322
Nishigaki H, Ito C, Manabe A, Kumagai M, Coustan-Smith E, Yanishevski Y, Behm FG, Raimondi SC, Pui CH, Campana D . Prevalence and growth characteristics of malignant stem cells in B-lineage acute lymphoblastic leukemia Blood 1997 89: 3735–3744
Nishihara M, Wada Y, Ogami K, Ebihara Y, Ishii T, Tsuji K, Ueno H, Asano S, Nakahata T, Maekawa T . A combination of stem cell factor and granulocyte colony-stimulating factor enhances the growth of human progenitor B cells supported by murine stromal cell line MS-5 Eur J Immunol 1998 28: 855–864
Ito K, Tezuka H, Sakoda H, Konno M, Nagata K, Uchiyama T, Uchino H, Mori KJ . Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow Exp Hematol 1989 17: 145–153
Breems DA, Blockland EAW, Neben S, Plomacher RE . Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay Leukemia 1994 8: 1095–1104
Fazekas S, Groth ST . The evaluation of limiting dilution assays J Immunol Meth 1982 49: 11–23
Acknowledgements
We are grateful to Novartis Pharma, Inc. for providing STI571 and to Kirin Brewery Co. Ltd. for providing MS-5.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kawaguchi, Y., Jinnai, I., Nagai, K. et al. Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells. Leukemia 15, 590–594 (2001). https://doi.org/10.1038/sj.leu.2402068
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402068
Keywords
This article is cited by
-
Adhesion-dependent growth of primary adult T cell leukemia cells with down-regulation of HTLV-I p40Tax protein: a novel in vitro model of the growth of acute ATL cells
International Journal of Hematology (2008)
-
Functional characterization of human CD34+ cells that express low or high levels of the membrane antigen CD111 (nectin 1)
Leukemia (2003)
-
Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay
Leukemia (2002)
-
Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571
Leukemia (2002)